Inhibition of adhesion of Clostridium difficile to human intestinal cells after treatment with serum and intestinal fluid isolated from mice immunized with nontoxigenic C. difficile membrane fraction

Microbial Pathogenesis

Volumn 81, Issue , 2015, Pages 1-5

  Senoh, Mitsutoshi ^a   Iwaki, Masaaki ^a   Yamamoto, Akihiko ^a   Kato, Haru ^a   Fukuda, Tadashi ^a   Shibayama, Keigo ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Adhesion; Clostridium difficile; Membrane fraction; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM ADHERENCE; BACTERIUM ISOLATION; CACO 2 CELL LINE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; FEMALE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; INTESTINE CELL; INTESTINE FLUID; MOUSE; NONHUMAN; NONTOXIGENIC CLOSTRIDIUM DIFFICILE; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; SERUM; VACCINATION; ANIMAL; BLOOD; DRUG EFFECTS; EPITHELIUM CELL; IMMUNOLOGY; INTESTINE MUCOSA; MICROBIOLOGY; PROCEDURES;

CLOSTRIDIUM DIFFICILE; MUS;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL ADHESION; BACTERIAL VACCINES; CACO-2 CELLS; CLOSTRIDIUM DIFFICILE; EPITHELIAL CELLS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; MICE; VACCINATION;

EID: 84924603401     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2015.03.001     Document Type: Article

References (29)

1. Ricciardi R., Nelson J., Griffith J.L., Concannon T.W. Do admissions and discharges to long-term care facilities influence hospital burden of Clostridium difficile infection?. J.Hosp. Infect. 2012, 80:156-161.
2. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Society for healthcare epidemiology of America; infectious diseases society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 2010, 31:431-455.
3. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 2009, 7:526-536.
4. Miller B.A., Chen L.F., Sexton D.J., Anderson D.J. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect. Control Hosp. Epidemiol. 2011, 32:387-390.
5. Iv E.C., Iii E.C., Johnson D.A. Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J. Gastrointest. Pharmacol. Ther. 2014, 5:1-26.
6. Venugopal A.A., Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin. Infect. Dis. 2012, 54:568-574.
7. Kelly C.P., Lamont J.T. Clostridium difficile-more difficult than ever. N.Engl. J. Med. 2012, 59:1932-1940.
8. Surawicz C.M., McFarland L.V., Greenberg R.N., Rubin M., Fekety R., Mulligan M.E., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis. 2012, 31:1012-1017.
9. Maroo S., Lamont J.T. Recurrent Clostridium difficile. Gastroenterology 2006, 130:1311-1316.
10. Tulli L., Marchi S., Petracca R., Shaw H.A., Fairweather N.F., Scarselli M., et al. CbpA: a novel surface exposed adhesin of Clostridium difficile targeting human collagen. Cell. Microbiol. 2013, 15:1674-1687.
11. Barketi-Klai A., Hoys S., Lambert-Bordes S., Collignon A., Kansau I. Role of fibronectin-binding protein A in Clostridium difficile intestinal colonization. J.Med. Microbiol. 2011, 60:1155-1161.
12. Calabi E., Calabi F., Phillips A.D., Fairweather N.F. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect. Immun. 2002, 70:5770-5778.
13. Kovacs-Simon A., Leuzzi R., Kasendra M., Minton N., Titball R.W., Michell S.L. Lipoprotein CD0873 is a novel adhesin of Clostridium difficile. J.Infect. Dis. 2014, 210:274-284.
14. Péchiné S., Hennequin C., Boursier C., Hoys S., Collignon A. Immunization using GroEL decreases Clostridium difficile intestinal colonization. PLoS One 2013, 8:e81112.
15. Ní Eidhin D.B., O'Brien J.B., McCabe M.S., Athié-Morales V., Kelleher D.P. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol. Med. Microbiol. 2008, 52:207-218.
16. Péchiné S., Janoir C., Boureau H., Gleizes A., Tsapis N., Hoys S., et al. Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine 2007, 25:3946-3954.
17. Stubbs S.L., Brazier J.S., O'Neill G.L., Duerden B.I. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J.Clin. Microbiol. 1999, 37:461-463.
18. Kato H., Kato N., Watanabe K., Yamamoto T., Suzuki K., Ishigo S., et al. Analysis of Clostridium difficile isolates from nosocomial outbreaks at three hospitals in diverse areas of Japan. J.Clin. Microbiol. 2001, 39:1391-1395.
19. Mukherjee K., Karlsson S., Burman L.G., Akerlund T. Proteins released during high toxin production in Clostridium difficile. Microbiology 2002, 148:2245-2253.
20. Pang Z., Nakagami H., Osako M.K., Koriyama H., Nakagami F., Tomioka H., et al. Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E1256-E1263.
21. Cerquetti M., Serafino A., Sebastianelli A., Mastrantonio P. Binding of Clostridium difficile to Caco-2 epithelial cell line and to extracellular matrix proteins. FEMS Immunol. Med. Microbiol. 2002, 32:211-218.
22. Donald R.G., Flint M., Kalyan N., Johnson E., Witko S.E., Kotash C., et al. Anovel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology 2013, 159:1254-1266.
23. Siddiqui F., O'Connor J.R., Nagaro K., Cheknis A., Sambol S.P., Vedantam G., et al. Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive Clostridium difficile but does not prevent colonization. J.Infect. Dis. 2012, 205:128-133.
24. Nagaro K.J., Phillips S.T., Cheknis A.K., Sambol S.P., Zukowski W.E., Johnson S., et al. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C.difficile. Antimicrob. Agents Chemother. 2013, 57:5266-5270.
25. Sambol S.P., Merrigan M.M., Tang J.K., Johnson S., Gerding D.N. Colonization for the prevention of Clostridium difficile disease in hamsters. J.Infect. Dis. 2002, 186:1781-1789.
26. Kuehne S.A., Cartman S.T., Heap J.T., Kelly M.L., Cockayne A., Minton N.P. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-713.
27. Tickler I.A., Goering R.V., Whitmore J.D., Lynn A.N., Persing D.H., Tenover F.C. Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013. Antimicrob. Agents Chemother. 2014, 58:4214-4218. For the Healthcare Associated Infection Consortium.
28. Bauer M.P., Notermans D.W., van Benthem B.H., Brazier J.S., Wilcox M.H., Rupnik M., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
29. Kato H., Kato H., Ito Y., Akahane T., Izumida S., Yokoyama T., et al. Typing of Clostridium difficile isolates endemic in Japan by sequencing of slpA and its application to direct typing. J.Med. Microbiol. 2010, 59:556-562.